Latest News & Features
Americas
A split US Court of Appeals for the Federal Circuit has declined to rehear a generic drug labelling dispute between Teva and GlaxoSmithKline. 14 February 2022
Generics
Sun Pharmaceuticals and Lupin Pharmaceuticals have decided to settle a patent suit related to Sun’s Bromsite eye drops, invalidating an opinion handed down by the US District Court for the District of New Jersey in September. 10 February 2022
Biotechnology
Chiara Banas, patent scientist at EIP, queries the gender gap in life sciences, and shares how her own experiences could prefigure change. 10 February 2022
Africa
Humanitarian organisation Médecins Sans Frontières has called for the South African government to seek the revocation of COVID-19-related patents granted to Eli Lilly and Moderna. 10 February 2022
article
For decades the European Commission and EU member states have worked towards creating a pan-European Unified Patent Court. In August the German Constitutional Court issued a landmark decision taking us a step closer to this being a reality. Recent developments mean that the UPC is now in its Provisional Application Period, and companies will be deciding how to use the new system. 10 February 2022
Generics
AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents. 8 February 2022
Europe
The European Commission will unveil plans to make supplementary protection certificates more accessible and efficient for pharmaceutical companies to register and enforce by the end of March. 8 February 2022
Big Pharma
Pharmaceutical industry consortium PhRMA has asked the Office of the US Trade Representative to put the European Union, the World Trade Organization and the UK on a watch list of trading partners that could “weaken” IP rights. 7 February 2022
Big Pharma
Pfizer has sued two of its former executive staffers, alleging that they stole trade secrets related to diabetes medication before leaving the company. 3 February 2022
Big Pharma
Gilead Sciences has agreed to pay $1.25 billion upfront with additional royalties to GlaxoSmithKline subsidiary ViiV Healthcare to settle claims that it infringed HIV drug patents. 3 February 2022